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Background: Fungal skull base osteomyelitis (SBO) is a severe complication of otitis externa or sinonasal infection,
and is mainly caused by Aspergillus species. Here we investigate innate and adaptive immune responses in patients
with Aspergillus SBO to identify defects in the immune response that could explain the susceptibility to this
devastating disease.
Methods: Peripheral blood mononuclear cells isolated from six patients with Aspergillus SBO and healthy volunteers
were stimulated with various microbial stimuli, among which also the fungal pathogens Candida albicans and
Aspergillus fumigatus. The proinflammatory cytokines IL-6, TNFα and IL-1β, and the T-helper cell-derived cytokines
IFNγ, IL-17 and IL-22 were measured in cell culture supernatants by ELISA.
Results: Proinflammatory cytokine responses did not differ between SBO patients and healthy volunteers. The
Candida- and Aspergillus-specific Th17 response (production of IL-17 and IL-22) was significantly decreased in the
SBO patients compared to healthy individuals, while Th1 cytokine response (IFNγ production) did not differ
between the two groups.
Conclusions: We show that patients with Aspergillus skull base osteomyelitis infection have specific defects in Th17
responses. Since IL-17 and IL-22 are important for stimulating antifungal host defense, we hypothesize that strategies
that have the ability to improve IL-17 and IL-22 production may be useful as adjuvant immunotherapy in patients with
Aspergillus SBO.
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Skull base osteomyelitis (SBO) is a rare but life-
threatening infection, which originates either from the
external ear canal or the paranasal sinus. Infiltrative
growth from the external acoustic duct into the tem-
poral bone is also termed malignant or invasive otitis
externa [1]. This aggressive infection is usually caused
by Pseudomonas aeruginosa, sometimes by fungal path-
ogens (mainly Aspergillus spp.), and in a minority of
cases by other bacteria (such as Staphylococci, Proteus
and Klebsiella) [2-4]. Besides an otologic origin of infec-
tion, sinusitis is the second major cause of skull base
osteomyelitis. Although this is a rare complication,* Correspondence: mihai.netea@radboudumc.nl
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unless otherwise stated.infections of the frontal, ethmoid, sphenoid and maxil-
lary sinus can spread to the orbital and frontal bone, cli-
vus and petrous apices. A distinct form of sinusitis is
fungal rhinosinusitis. This has a broad clinical spectrum
ranging from chronic forms with gradually progressing
osteomyelitis to necrotizing angioinvasive disease. Asper-
gillus, Rhizopus and Fusarium are the most commonly
identified fungi. Fungal skull base osteomyelitis due to As-
pergillus is an infection with considerable morbidity and
mortality rates up to 50%. In addition to aggressive surgical
debridement and systemic antifungal therapy, the mainstay
of therapy includes, whenever possible, correction of the
underlying immunologic defect.
Spores of Aspergillus are continuously inhaled and
therefore fungal colonization of the upper airways is
common. Despite this continuous exposure, invasive dis-
ease caused by Aspergillus in an immunocompetent host. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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may be present in patients with fungal SBO, often the only
apparent risk factor identified is a chronic external otitis or
an anatomical obstruction of the sinuses (e.g. nasal polyps
or chronic inflammation of the mucosa). The extent of tis-
sue invasion in these patients may vary depending on the
underlying immune status of the host. In the present study
we present six cases of skull base osteomyelitis due to As-
pergillus fumigatus and Aspergillus flavus, in whom we in-
vestigated whether the innate and adaptive immune




We describe six patients who were admitted to the
Radboud University Medical Center with a culture-proven
invasive Aspergillus osteomyelitis of the skull. All patients
were diagnosed between September 2007 and July 2010.
Charts were reviewed for data on demographics, risk fac-
tors, presenting symptoms, treatment, side effects, micro-
biology results, and clinical outcome. Response was defined
according to the revised MSG/EORTC consensus group
definition [5]. Patients and healthy volunteers, who served
as healthy controls in the immunological experiments, were
asked for blood donations. The blood samples were col-
lected from patients and healthy volunteers after informed
consent was obtained in accordance to Good Clinical prac-
tice, the Declaration of Helsinki, and the approval of the
Arnhem-Nijmegen Ethics Committee (nr.2010/104).
Stimuli
E.coli lipopolysaccharide (LPS) (10 ng/ml) (TLR4 ligand,
E. coli serotype O55:B5, Sigma-Aldrich St. Louis, MO
USA); heat-killed Staphylococcus aureus clinical isolate
(S. aureus) (1×107/ml); heat-killed Candida albicans
yeast ATCC MYA-3573 (UC820) (C. albicans) (1×105/ml);
heat-killed Aspergillus fumigatus clinical isolate V05-27 (A.
fumigatus) conidia (1×107/ml) were cultured and isolated
as described previously [6].
Peripheral blood mononuclear cells (PBMCs) isolation
Fresh venous blood was drawn in 10 ml EDTA tubes
from patients and controls and processed in parallel
continuously from PBMC isolation to cytokine measure-
ment. Every patient gave blood only once. The blood
was diluted 1:1 with Phosphate Buffered Saline (PBS).
Subsequently PBMCs were isolated using Ficoll-paque
(GE Healthcare, Zeist, The Netherlands) density gradient
centrifugation. The PBMCs layer was collected and
washed twice in cold PBS. Cells were reconstituted in
RPMI-1640 culture medium (Dutch modification, Gibco,
Invitrogen, Breda, The Netherlands) supplemented with
10 μg/ml gentamicin, 10 mM L-glutamine and 10 mMpyruvate (Gibco). The cells were counted with a particle
counter (Beckmann Coulter, Woerden, The Netherlands)
and the concentration was adjusted to 5×106 cells/ml.
PBMCs stimulation
PBMCs were plated in a 96-well plate (Corning, NY,
USA) at a final concentration of 2.5×106/ml in an end
volume of 200 μl per well. Either medium or stimuli
were added. Cells were incubated at 37°C with 5% CO2,
after 24 or 48 hours or 7 days supernatants were col-
lected and stored at −20°C. Seven-day stimulations were
performed in the presence of 10% pooled human serum.
All stimulations assays were performed in duplicates.
Cytokines measurements
Cytokines were measured in the cell culture supernatants
using a commercial ELISA kit (IL-1β, TNFα, IL-17 and IL-
22: R&D Systems; IL-6 and IFNγ: Sanquin) according to
the instructions supplied by the manufacturer. Proinflam-
matory cytokines production was measured after 24 hours,
IFNγ after 48 hours and the T helper cytokines IL-22 and
IL-17 after 7 days of incubation.
Statistical analysis
The Mann–Whitney-U test was used to detect differences
between healthy controls and patients. A p-value of < 0.05
was considered statistically significant (* = p < 0.05, ** = p <
0.01 and *** = p < 0.001). Graphs represent cumulative re-
sults of all performed experiments and are presented as
mean ± standard error of the mean. Data were analyzed
with GraphPad Prism v 5.0.
Results
Demographic characteristics of patients and controls
Patients
Three male and three female patients were included in
the study with age ranging from 37 to 87 years (mean:
59.5 years). Infections were located in the sphenoid,
mastoid or ethmoid bones with partial affection of sinus
cavernosus, frontal or temporal lobe or orbita. All pa-
tients presented with cranial nerve palsy. In four cases
the diagnosis was additionally confirmed by a positive
histology. One patient developed Aspergillus osteomye-
litis following trans-sphenoidal surgery for pituitary ad-
enoma with a chronic myeloid leukemia (CML) in the
past; two had a history of diabetes; all other patients had
primary fungal infection of sinus or mastoid.
Controls
Three male and three female healthy volunteers were in-
cluded in the control group; the age ranged from 24 to
60 years (mean: 42.7 years). Three of the patients were
recruited from the blood bank via the blood donor ser-
vice (Sanquin, Nijmegen, The Netherlands) and three
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nation. All volunteers were healthy and did not have an
immunologically relevant medical history.
Microbiology
Culture and molecular identification confirmed the fun-
gal infection and susceptibility to antifungal drugs was
tested (Table 1). Galactomannan assay was performed in
all patients on serum and in 4 patients on cerebrospinal
fluid. All results were negative (index < 0.5).
Treatment, clinical outcome and blood sampling
Surgical debulking was performed in all patients. All pa-
tients were initially treated with systemic antifungal drug
therapy. Voriconazole was first line treatment in all pa-
tients. Four patients were treated with voriconazole
monotherapy. One patient was concomitantly treated
with liposomal amphotericine B during the first months
of treatment. Posaconazole was used after induction
treatment in two patients. Duration of therapy (from 4.5
to 35 months) was guided by clinical response and im-
aging, with follow-up from 8 to 38 months. Four pa-
tients had a complete response, one had a relapse, and
one died due to respiratory failure. During infection the
leukocytes count was normal in five of six patients, ran-
ging from 6.6 × 109/l to 9.1 × 109/l. One patient had a
decreased leukocyte count of 3.1 × 109/l and slightly de-
creased numbers in the differential blood count. Three
patients had normal and three patients had increased
CRP values (11 mg/l, 14 mg/l and 32 mg/l). Blood sam-
ples for immunological assays were taken after clinical
improvement and response to the therapy: in three pa-
tients during the first month after onset of the antifungal
therapy, while in three patients blood was collected after
the pharmacological therapy had been finished and the
infection did not recur.
Patients with Aspergillus SBO do not differ from healthy
controls in their production of proinflammatory cytokines
To investigate the innate immune response, PBMCs iso-
lated from six patients with Aspergillus SBO wereTable 1 Anti-fungal susceptibility of microbiological isolates
Case Isolate AMT (mg/L) ITC (mg/L) VOR (
1 A. fumigatus *
2 A. fumigatus 1 1 2
3 A. fumigatus 0.5 0.063 0.125
4 A. fumigatus 1 0.25 1
5 A. fumigatus **
6 A. flavus 1 0.063 1
*MIC impossible because of poor sporulation. Analysis of Cyp51A-gene: no TR/L98H
**No isolate available for susceptibility testing.
MIC values of fungal isolates tested for Amphotericin B (AMT), Itraconazole (ITC), Vo
Caspofungin (CASPO) are listed.stimulated with Aspergillus fumigatus, E. coli LPS and
different pathogens and compared with healthy controls
(Figure 1 A-C). Neither the unspecific LPS-stimulation,
nor the pathogen-specific C. albicans, S. aureus, and
disease-specific A. fumigatus stimulations showed dif-
ferences in the production of the inflammatory cyto-
kines IL-1β, TNFα and IL-6.Patients with Aspergillus SBO are deficient in Aspergillus-
induced IL-17 and IL-22 but not in IFNγ production
While the recognition and initiation of inflammatory
cytokine responses revealed to be intact, we wanted to
address the question whether defects in the acquired im-
mune response might explain the high susceptibility to
the fungal infection of the six fungal SBO patients in-
cluded in this study. PBMCs were stimulated with C.
albicans and S. aureus, serving as positive controls for
the induction of IFNγ, IL-17 and IL-22, and A. fumiga-
tus, to investigate pathogen-specific deficiencies. The
Th1 response, shown by IFNγ production, did not differ
between patients with Aspergillus SBO and healthy controls
(Figure 1D). In contrast, IL-22 and IL-17 production was
significantly reduced after stimulation with both fungal
pathogens C. albicans and A. fumigatus (Figure 1E-F).Discussion
In this study, we describe the clinical presentation and
immunological features of six patients with Aspergillus
SBO. None of the patients were neutropenic at the time
of the infection or had a known primary immunodefi-
ciency. We hypothesized that specific defects in Asper-
gillus-specific innate and/or adaptive immune response
would contribute to the unsuccessful fungal clearance
and extent of the Aspergillus infection in our patients.
Therefore, we investigated host responses in six patients
with Aspergillus-SBO. While the innate responses were
not different from a healthy control group, Th17 cyto-
kines induced by fungal pathogens such as C. albicans
and A. fumigatus were shown to be defective in the pa-






riconazole (VOR), Anidulafungin (Anidula), Posconazole (POSA) and
Figure 1 SBO patients have an intact innate immune response, but are defective in IL-17 and IL-22 production. PBMCs stimulated with
E. coli LPS, heat killed C. albicans yeast, S. aureus and A. fumigatus were cultured for 24 hours 48 hours or 7 days respectively. The innate cytokines
IL-1β (A), TNFα (B), IL-6 (C) (after 24 hours) and adaptive cytokines IFNγ (D) (after 48 hours) and IL-17 (E) /IL-22 (F) (after 7 days) were measured
in the cell culture supernatant by ELISA. Controls (black bars, n = 6) compared with SBO patients (white bars, n = 6).
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dependent on the site of infection and immune status of
the host. Aspergillus osteomyelitis is increasingly being re-
ported [7] with approximately 15% of the cases affecting
the skull base [7,8]. Aspergillus SBO is a severe complica-
tion of otitis externa or invasive sinonasal aspergillosis, in
which most patients become infected via the tympanic cav-
ity or the sinus [2].
The main risk factors described for invasive Aspergillus-
SBO are systemic immunosuppression [9] and hematologic
malignancies (12%) [7,10]. One patient included in this
study suffered from chronic myeloid leukemia, and he was
treated with the tyrosine kinase inhibitor imatinib at the
time of the infection. Two patients had diabetes mellitus
and three suffered from sinusitis, which have been reported
in previous studies as risk factors [7,10]. Although almost
all patients had normal leukocyte counts (one was slightly
decreased), additional factors influencing the immune re-
sponse such as the imatinib treatment, diabetes or the high
age of one patient might affect the IL-17 response as well.
Normal monocyte-derived cytokine levels point to a spe-
cific T-cell defect.
Early recognition and therapeutic intervention in invasive
sinonasal aspergillosis with systemic antifungal therapy and
surgical resection and/or debridement is important. In ac-
cordance with the current guidelines, all patients included
in the present study were treated with surgical debridementof the infected bone and systemic antifungal drug therapy,
of which voriconazole was the drug of first choice. We ob-
served a mortality of 1 out of 6 in the patients included in
the present study, which is in line with the reported poor
clinical outcome of Aspergillus osteomyelitis, which has a
25% 12-weeks mortality [11].
Why did our patients without an apparent severe im-
munodeficiency get invasive aspergillosis? Aspergillus spp.
are an occasional commensal of the external ear and para-
nasal sinuses [12], but invasive disease is very rare. Chronic
infection leading to damage of the epithelial barrier is an
important entry for the fungus to infect the host. Recogni-
tion of Aspergillus will result in the production of proin-
flammatory cytokines that will recruit immune cells to
clear the infection [13]. In the present study, patients with
Aspergillus SBO showed normal production of the cyto-
kines TNFα, IL-1β and IL-6 after stimulation with A. fumi-
gatus, C. albicans, the Gram-positive bacterium S. aureus,
and the Gram-negative cell wall component E. coli LPS.
Therefore, a defect in the production of monocyte-derived
proinflammatory cytokines is unlikely to be the cause of
the susceptibility of fungal SBO in our patients. Acquired
adaptive T-helper responses also play an important role in
anti-Aspergillus host defense. The protective role of IFNγ
in the Aspergillus-specific host response has been reported
previously [14]. We did not observe a difference in Asper-
gillus-specific IFNγ production; Candida-specific IFNγ
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tion, but this was not significant. However, the Aspergillus-
specific Th17 response was significantly lower in SBO
patients compared to the healthy control group. In
addition, this was also observed, when the cells were stimu-
lated with Candida. IL-17 is a characteristic cytokine pro-
duced by Th17 cells. Th17 cells are crucial for neutrophil
recruitment and controlling fungal invasion at the level of
mucosae and skin [15]. Similar to IL-17, the IL-22 produc-
tion was significantly decreased in SBO patients compared
to healthy controls in the present study. IL-22 is also pro-
duced by Th17 cells [16] and shares many effector func-
tions with IL-17 [17]. IL-22 plays a predominant role in
mucosal host defense [18] by inducing anti-microbial pep-
tides produced by epithelial cells, which can kill microor-
ganisms directly [19].
In a previous study we have identified that IFNγ treat-
ment had beneficial effects on the immune status including
IL-17 and IL-22 responses in a case series of patients with
invasive fungal infections [20]. This suggests that adjuvant
therapy with recombinant IFNγ may improve the outcome
of patients with a severe fungal SBO. Another treatment
option would be to increase the differentiation into Th1
and Th17 cells by GM-CSF [21]. GM-CSF was shown to
enhance the secretion of inflammatory cytokines [22] and
antigen-presentation [23] under inflammatory conditions.
It also induces the differentiation of progenitors cells into
monocytes and granulocytes [24]. Therefore, GM-CSF
might have beneficial effects on immune cells in the skin
even in the setting of an IL-17/IL-22 deficiency [25]. One
might speculate about supplementary therapy with recom-
binant IL-22, since IL-22 was shown to have beneficial ef-
fect in wound healing processes and pre-clinical studies
have shown good toleration of administration of the drug
[26].
We are aware of the fact that the sample size of six pa-
tients is inevitably small. A type I error of 5%, meaning
the likelihood to accept the hypothesis that Aspergillus
SBO patients and control do not differ in their Aspergil-
lus-specific IL-17 response was assumed. Using the cal-
culated means, standard deviations of the experimental
measurements and sample size of both groups we calcu-
lated a statistical power of 81%. Thus, the Type II error,
meaning the hypothesis that patients and controls differ
in their IL-17 response is neglected, lay with 19% in an
acceptable range for medical tests. Retrospectively, due
to the differences observed, the sample size of 6 donors
was the minimal size needed to detect statistically rele-
vant differences. Further sample size independent calcu-
lation revealed an effect size of 1.5, which indicates that
Aspergillus SBO has a statistically strong effect on the
Aspergillus-specific IL-17 production.
Nevertheless, there are also some limitations of the
study. One note of caution is that while patients andcontrols matched regarding their gender, the patients
were in average older, although the 15 years difference is
unlikely to explain the significant differences observed.
Further, it remains unknown whether the defective IL-17
and IL-22 production was the consequence of a primary
defect (e.g. genetic) or was secondary to a predisposing
factor of the Aspergillus SBO patients (e.g. the antifungal
treatment). Nevertheless, the present study contributes
to understanding the specific defective host defense
mechanisms underlying SBO due to Aspergillus.
Conclusions
This is the first study describing a deficiency in fungal-
induced Th17 responses in patients with Aspergillus
skull base osteomyelitis. Future studies are needed to
validate this observation and its clinical implication, es-
pecially the potential beneficial effects of immunother-
apy aimed to boost Th17 responses.
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